Last reviewed · How we verify
amisulpride with Clozapine
At a glance
| Generic name | amisulpride with Clozapine |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (PHASE2)
- Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy (PHASE4)
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
- Optimization of Treatment and Management of Schizophrenia in Europe (PHASE4)
- Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amisulpride with Clozapine CI brief — competitive landscape report
- amisulpride with Clozapine updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI